Tianda Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Tianda Pharmaceuticals hat ein Gesamteigenkapital von HK$591.9M und eine Gesamtverschuldung von HK$104.9M, was einen Verschuldungsgrad von 17.7% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen HK$917.3M bzw. HK$325.4M.

Wichtige Informationen

17.7%

Verhältnis von Schulden zu Eigenkapital

HK$104.85m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	HK$170.87m
Eigenkapital	HK$591.94m
Gesamtverbindlichkeiten	HK$325.35m
Gesamtvermögen	HK$917.29m

Jüngste Berichte zur Finanzlage

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Mar 02

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

May 23

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Dec 06

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Jan 11

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Aug 05

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Dec 11

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 455Die kurzfristigen Aktiva des Unternehmens (HK$344.2M) übersteigen seine kurzfristigen Passiva (HK$313.3M).

Langfristige Verbindlichkeiten: 455Die kurzfristigen Vermögenswerte des Unternehmens (HK$344.2M) übersteigen seine langfristigen Verbindlichkeiten (HK$12.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 455 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 455Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 17.7% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: 455 auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: 455 verfügt über eine ausreichende Liquiditätsreserve für 1.3 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 23.8% pro Jahr abnimmt.

Tianda Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen